These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24261554)

  • 41. Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype.
    Driessler F; Miguelino MG; Pierce GF; Peters RT; Sommer JM
    Blood Coagul Fibrinolysis; 2017 Oct; 28(7):540-550. PubMed ID: 28486277
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
    Berntorp E; Negrier C; Gozzi P; Blaas PM; Lethagen S
    Haemophilia; 2016 May; 22(3):389-96. PubMed ID: 26863900
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A.
    Novembrino C; Boscolo Anzoletti M; Mancuso ME; Shinohara S; Peyvandi F
    Haemophilia; 2019 May; 25(3):521-526. PubMed ID: 31044485
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues.
    Kitchen S; Kershaw G; Tiefenbacher S
    Haemophilia; 2016 Jul; 22 Suppl 5():72-7. PubMed ID: 27405680
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative analysis of chromogenic vs clot.based one stage APTT assay for determination of factor VIII level.
    Baig MA; Swamy KB
    Indian J Pathol Microbiol; 2021; 64(1):123-127. PubMed ID: 33433421
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.
    Oldenburg J; Hay CRM; Jiménez-Yuste V; Peyvandi F; Schved JF; Szamosi J; Winding B; Lethagen S
    BMJ Open; 2019 May; 9(5):e028012. PubMed ID: 31152037
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.
    Lehtinen AE; Baghaei F; Astermark J; Holme PA
    Haemophilia; 2022 Sep; 28(5):713-719. PubMed ID: 35575446
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Considerations on activity assay discrepancies in factor VIII and factor IX products.
    Ovanesov MV; Jackson JW; Golding B; Lee TK
    J Thromb Haemost; 2021 Sep; 19(9):2102-2111. PubMed ID: 34145730
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    Haemophilia; 2017 May; 23(3):408-416. PubMed ID: 28233383
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory.
    Cauchie M; Toelen J; Peerlinck K; Jacquemin M
    Haemophilia; 2013 May; 19(3):e133-8. PubMed ID: 23374099
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
    Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
    J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FIXa and FXIa activation.
    Brophy DF; Martin EJ; Ninivaggi M; Mohammed BM; Barrett JC; Kuhn J; Nolte ME; Waters EK; Ezban M
    Haemophilia; 2018 Sep; 24(5):815-822. PubMed ID: 30112856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme.
    van Moort I; Meijer P; Priem-Visser D; van Gammeren AJ; Péquériaux NCV; Leebeek FWG; Cnossen MH; de Maat MPM
    Haemophilia; 2019 Jan; 25(1):162-169. PubMed ID: 30488994
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Performance evaluation of Revohem
    Suzuki A; Suzuki N; Kanematsu T; Shinohara S; Arai N; Kikuchi R; Matsushita T
    Int J Lab Hematol; 2019 Oct; 41(5):664-670. PubMed ID: 31271527
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Functional characteristics of N8, a new recombinant FVIII.
    Christiansen ML; Balling KW; Persson E; Hilden I; Bagger-Sørensen A; Sørensen BB; Viuff D; Segel S; Klausen NK; Ezban M; Lethagen S; Steenstrup TD; Kjalke M
    Haemophilia; 2010 Nov; 16(6):878-87. PubMed ID: 20546031
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management.
    Müller J; Goldmann G; Marquardt N; Pötzsch B; Oldenburg J
    Hamostaseologie; 2020 Nov; 40(S 01):S15-S20. PubMed ID: 33187006
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world data.
    Farahbakhshian S; Fan Q; Schultz BG; Princic N; Park J; Bullano M
    J Med Econ; 2023; 26(1):1278-1286. PubMed ID: 37787429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.
    Carcao M; Shapiro A; Staber JM; Hwang N; Druzgal C; Lieuw K; Belletrutti M; Thornburg CD; Ahuja SP; Morales-Arias J; Dumont J; Miyasato G; Tsao E; Jain N; Pipe SW
    Haemophilia; 2018 Mar; 24(2):245-252. PubMed ID: 29436077
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Accurate measurement of extended half-life and unmodified factor VIII low levels with one-stage FVIII assays is dependent on the matrix of calibration curves.
    Van den Bossche D; Toelen J; Schoeters J; Van Horenbeeck I; Vanlinthout I; Debasse M; Peerlinck K; Jacquemin M
    Haemophilia; 2019 Jan; 25(1):e19-e26. PubMed ID: 30589148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.